- Breast cancer continues to be the most commonly diagnosed cancer among U.S. women, excluding nonmelanoma skin cancer
- Izotropic is preparing to revolutionize breast cancer imaging with its flagship IzoView Breast CT Imaging System
- In anticipation of future commercialization, Izotropic is initiating a strategic awareness and engagement campaign
Accurate detection and diagnosis remain critical challenges in the fight against breast cancer, especially for women with dense breast tissue where mammography falls short. Izotropic (CSE: IZO) (OTCQB: IZOZF) is at the forefront of addressing these gaps through its IzoView Breast CT Imaging System, a contrast-enhanced CT platform designed for enhanced screening precision. The company is actively preparing for the commercialization of IzoView, signaling a pivotal development in breast cancer imaging.
Breast cancer continues to be the most diagnosed cancer among U.S. women (excluding nonmelanoma skin cancer), with approximately 316,950 new cases of invasive breast cancer expected in women in 2025, along with 2,800 cases in men (ibn.fm/zRTJQ). The disease remains the second-leading cause of cancer-related death among women, with more than 42,000 women and 510 men projected to die of breast cancer this year (ibn.fm/jNdXe).
Despite advances in early detection and treatment, only about 66% of cases are diagnosed at a localized stage, when five-year survival rates can exceed 99% (ibn.fm/mwubn). Women with dense breast tissue, nearly half of those in the United States, face higher risk and lower detection rates using conventional mammography and tomosynthesis, which are less sensitive in dense tissue (ibn.fm/CNkv3).
Given these disparities, the need for improved screening, diagnostic accuracy and treatment guidance is urgent. Dense breast tissue not only elevates cancer risk but also masks tumors under traditional 2D imaging, often resulting in delayed detection and treatment. While survival rates are encouraging overall, outcomes worsen substantially when cancers are diagnosed at regional or distant stages, where five-year survival drops significantly. This underscores a critical unmet medical need for diagnostic tools that reliably detect cancers regardless of tissue density and provide earlier, more actionable clinical insight.
Against this backdrop, Izotropic is preparing to revolutionize breast cancer imaging with its flagship IzoView Breast CT Imaging System, a dedicated breast imaging platform offering high-resolution, true 3D visualization without breast compression. According to the company, the system was advanced from academic innovation to commercial readiness by its expert in-house team using exclusively licensed technology that was developed at the University of California, Davis. The platform system, which integrates proprietary mechanical design, patented hardware innovations, optimizes diagnostic accuracy, patient comfort and clinical workflow. The company also has proprietary AI-driven enhancements protected as trade secrets to support radiologist performance.
In anticipation of future commercialization, Izotropic is initiating a strategic awareness and engagement campaign (ibn.fm/Zu0b5). The company’s efforts will center on a consistent and compelling stream of development-related news to educate global audiences on the transformative value of dedicated breast CT technology and will spotlight how IzoView stands apart from traditional breast imaging modalities and competing breast CT systems, positioning it as a true game-changer in the field.
In addition, the company will also launch a new podcast and new website: breastct.com, a dedicated educational hub aimed at informing patients, clinicians and advocates about breast CT technology and its advantages over standard imaging. This outreach initiative includes a steady stream of development-related updates intended to raise global awareness of IzoView’s potential to reshape breast imaging workflows and improve outcomes. By sharing research, regulatory progress, and technical differentiation, Izotropic is working to establish IzoView as a new standard in breast cancer screening.
Taken together, the breadth of breast cancer incidence, the substantial mortality burden and the limitations of current screening technologies make the case for innovation unmistakable. Izotropic’s IzoView system, and its thoughtful regulatory and educational strategy, stand poised to address long-standing gaps in detection and diagnosis. As the company moves toward securing regulatory approval following a successful FDA pre-submission and eventual clinical study for PMA submission, IzoView may offer a breakthrough tool that empowers earlier detection, reduces false negatives, and ultimately helps save lives.
For more information, visit the company’s website at www.IzoCorp.com
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN